• The calcium-channel blocker nimodipine, the only drug known to improve outcomes following subarachnoid haemorrhage:
  • Acts as a calcium channel antagonist:
    • Blocks the slow calcium channel of vascular smooth muscle and cardiac muscle
    • High lipid solubility of nimodipine allows it to cross the BBB offering a more cerebral selective effect over other calcium channel blockers
  • Recommended to be administered orally to all patients from the time of presentation:
    • Should be continued for 21 days
    • Administered at a dose of 60mg PO every 4 hours
    • May be reduced to 30mg every 2 hours in the event of hypotension
    • In case oral administration is not possible nimodipine can be administered IV